Gland Pharma shares fall over 4% after weak Q3 result, Jefferies target price (...)
Gland Pharma share price: Revenue from operations fell 10% year-on-year to Rs 1,384 crore. EBITDA increased by 1% year-on-year to Rs 360 crore, with margins improving by 300 basis points to 26%. R&D expenses were Rs 43.7 crore, making up 4.3% of the (...)
Site référencé: The Economic Times
The Economic Times
Nifty’s weakness may persist, support at 24,000 : Analysts
11/08/2025
India is growing strong, but slowing down sequentially : Gustavo Medeiros
11/08/2025
Know Your Fund Manager : Siddharth Vora, Head - Investment Strategy & Fund Manager, PL Capital
10/08/2025
How to choose a mutual fund : A beginner’s simple step-by-step guide
10/08/2025
Midcap stocks still pricey ? Tata Mutual Fund's take on where to invest now
10/08/2025
Olectra Greentech Q1 Results : PAT rises 7% YoY to Rs 26 crore, revenue surges nearly 11%
10/08/2025
